Oki et al. (2012) provided the first evidence that transplantation of hiPSC-derived cells is a safe and efficient approach to promote recovery after stroke and can be used to supply the injured brain with new neurons for replacement. They transplanted neuroepithelial-like stem cells, generated from adult human fibroblast-derived iPSCs, into stroke-damaged mouse and rat striatum or cortex. The transplanted cells stopped proliferating after a while but have at least shown that they can survive without forming tumors for at least a period of 4 months. This 4-months observation period warrants lack of rejection of the transplanted cells and creates an optimal setting to evaluate tumorigenicity. The iPSCs successfully differentiated neurons in intrastriatal grafts sent axonal projections to the globus pallidus. Moreover, the grafted cells exhibited electrophysiological properties of mature neurons and most importantly received synaptic input from host neurons (Oki et al., 2012). There is not much data and research on the iPSCs regenerative ability in brain injury. Therefore, in order to establish its safety and effectiveness, much more studies and effort have to be done in that domain. After
